Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia

The treatment of chronic myeloid leukemia (CML) has been radically changed by the approval of tyrosine kinase inhibitors (TKIs), which target BCR-ABL1 kinase activity. CML is now managed as a chronic disease requiring long-term treatment and close molecular monitoring. It has been shown that in a su...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Oncol
Autors principals: Annunziata, Mario, Bonifacio, Massimiliano, Breccia, Massimo, Castagnetti, Fausto, Gozzini, Antonella, Iurlo, Alessandra, Pregno, Patrizia, Stagno, Fabio, Specchia, Giorgina
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2020
Matèries:
Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7280484/
https://ncbi.nlm.nih.gov/pubmed/32582549
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00883
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars